Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Oral HIF-PH Inhibitors for the Treatment of Renal Anemia in CKD Non-Dialysis and Dialysis: How Will U.S. Physicians and Payers Respond to This Novel Class? | Physician & Payer Forum | US | 2014
Renal anemia and hyperphosphatemia, or elevated serum phosphorous, are two primary complications of chronic kidney disease (CKD) that are treated with erythropoiesis-stimulating agents (ESAs) and…
Nephrology (Renal Anemia and Bone and Mineral Metabolism) | TreatmentTrends | US | Q3 2014
This quarterly report series covers the management of dialysis and mid- to late-stage chronic kidney disease (CKD) patients from the perspective of nephrologists. Emphasis is on anemia management (…
Nephrology (Renal Anemia and Bone and Mineral Metabolism) | TreatmentTrends | US | Q2 2014
This quarterly report provides a detailed analysis of emerging and current therapies in nephrology based on responses from surveyed U.S. nephrologists. Emphasis is on anemia management (ESAs and IV…
Renal Anemia in Chronic Kidney Disease Non-Dialysis | Chart Trends | China | 2014
Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications and a host of laboratory and patient demographic variables help define…
Nephrology (Renal Anemia and Bone and Mineral Metabolism) | TreatmentTrends | US | Q1 2014
This quarterly report provides a detailed analysis of emerging and current therapies in nephrology based on responses from surveyed U.S. nephrologists. Emphasis is on anemia management (ESAs and IV…